Press Releases
Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
Ceapro Announces Grant of Stock Options
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights
Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets
Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers
Ceapro Inc. Reports Record 2022 Second Quarter and Six-Month Financial Results and Provides Corporate Update
